| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA
|
Carmona-Bayonas, A.
|
|
|
32 |
7 |
p. 938-939
|
artikel
|
| 2 |
Building bridges between drug development and cancer science: a tribute to José Baselga's legacy
|
Hyman, D.M.
|
|
|
32 |
7 |
p. 825-828
|
artikel
|
| 3 |
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
|
Annala, M.
|
|
|
32 |
7 |
p. 896-905
|
artikel
|
| 4 |
Checkpoint inhibition: protecting against or predisposing for second primary tumors?
|
Suijkerbuijk, K.P.M.
|
|
|
32 |
7 |
p. 935
|
artikel
|
| 5 |
Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’
|
Fossard, G.
|
|
|
32 |
7 |
p. 945
|
artikel
|
| 6 |
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
|
Owen, C.N.
|
|
|
32 |
7 |
p. 917-925
|
artikel
|
| 7 |
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
|
Wang, J.Y.
|
|
|
32 |
7 |
p. 906-916
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
32 |
7 |
p. iii
|
artikel
|
| 9 |
ESMO pays tribute to Professor José Baselga
|
Peters, S.
|
|
|
32 |
7 |
p. 823-824
|
artikel
|
| 10 |
Estrogen and COVID-19: friend or foe?
|
Di Vincenzo, A.
|
|
|
32 |
7 |
p. 933-934
|
artikel
|
| 11 |
Genomic testing for targeted oncology drugs: hopes against hype
|
Dienstmann, R.
|
|
|
32 |
7 |
p. 837-838
|
artikel
|
| 12 |
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy
|
Fundytus, A.
|
|
|
32 |
7 |
p. 833-836
|
artikel
|
| 13 |
Immunotherapy use outside clinical trial populations: never say never?
|
Rzeniewicz, K.
|
|
|
32 |
7 |
p. 866-880
|
artikel
|
| 14 |
Multidisciplinary tumor boards present technical and financial challenges in the COVID-19 era
|
Schroeder, B.A.
|
|
|
32 |
7 |
p. 933
|
artikel
|
| 15 |
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
|
Laparra, A.
|
|
|
32 |
7 |
p. 936-937
|
artikel
|
| 16 |
Novel adjuvant options for cutaneous melanoma
|
Dimitriou, F.
|
|
|
32 |
7 |
p. 854-865
|
artikel
|
| 17 |
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds
|
Robbrecht, D.G.J.
|
|
|
32 |
7 |
p. 831-832
|
artikel
|
| 18 |
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
|
Rodríguez-Abreu, D.
|
|
|
32 |
7 |
p. 881-895
|
artikel
|
| 19 |
Reframing recalcitrance for small-cell lung cancer
|
Blackhall, F.H.
|
|
|
32 |
7 |
p. 829-830
|
artikel
|
| 20 |
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|
Dingemans, A.-M.C.
|
|
|
32 |
7 |
p. 839-853
|
artikel
|
| 21 |
Table of Contents
|
|
|
|
32 |
7 |
p. i-ii
|
artikel
|
| 22 |
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
|
Haslam, A.
|
|
|
32 |
7 |
p. 926-932
|
artikel
|
| 23 |
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
|
Soo, R.
|
|
|
32 |
7 |
p. 942-944
|
artikel
|
| 24 |
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
|
Tewari, K.S.
|
|
|
32 |
7 |
p. 940-941
|
artikel
|
Tijdschrift beschrijving